Bis(4-O-polyhexaose-thio)-phenyl ureas and method of use

Claim 2

A compound selected from those of the formula: ##STR4## wherein X is --SO 3 M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of trialkylamine (C 1 -C 6 ), piperidine, pyrazine, alkanolamine (C 2 -C 6 ) and cycloalkylamine (C 3 -C 6 ).

Claim 3

The compound according to claim 1, tetradecatriethylammonium N,N'-bis[4-[[2,3,6-tri-O-sulfo-4-O-(2,3,4,6-tetra-O-sulfo-α-D-glucopyranosyl)-β-D-glucopyranosyl]thio]phenyl]urea, where the structure is: ##STR5## wherein A is NH + (C 2 H 5 ) 3 .

Claim 4

The compound according to claim 1, tetradecasodium N,N'-bis[4-[[2,3,6-tri-O-sulfo-4-O-(2,3,4,6-tetra-O-sulfo-α-D-glucopyranosyl)-β-D-glucopyranosyl]thio]phenyl]urea, where the structure is: ##STR6##

Claim 5

A compound selected from those of the formula: ##STR7## wherein Y is --H or --COCH 3 .

Claim 6

A compound selected from those of the formula: ##STR7## wherein Y is --H or --COCH 3 .

Claim 7

The compound according to claim 4, N,N'-bis[4-[[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-β-D-glucopyranosyl]thio]phenyl]urea, where the structure is: ##STR8##

Claim 8

The compound according to claim 4, N,N'-bis[4-[[4-O-(α-D-glucopyranosyl)-β-D-glucopyranosyl]thio]phenyl]urea, where the structure is: ##STR9##

Claim 9

A method of modulating the complement system in a body fluid which comprises subjecting said body fluid to the action of an effective complement modulating amount of a pharmaceutically acceptable compound selected from those of the formula of claim 1.

Claim 10

The method according to claim 7, wherein the body fluid is blood serum.

Claim 11

A method of modulating the complement system in a warm-blooded animal which comprises administering to said warm-blooded animal an effective complement modulating amount of a pharmaceutically acceptable compound selected from those of the formula of claim 1.

Claim 12

The method according to claim 7 or 9, wherein the compound is tetradecatriethylammonium N,N'-bis[4-[[2,-3,6-tri-O-sulfo-4-O-(2,3,4,6-tetra-O-sulfo-α- D-glucopyranosyl)-β-D-glucopyranosyl]thio]phenyl]urea.

Claim 13

The method according to claim 7 or 9, wherein the compound is tetradecasodium N,N'-bis[4-[[2,3,6-tri-O-sulfo-4-O-(2,3,4,6-tetra-O-sulfo-α-D-glucopyranosyl)-β-D-glucopyranosyl]thio]phenyl]urea.

Claim 14

The method according to claim 9, wherein the compound is administered internally, topically, periodontally in the oral cavity, intra-articularly or parenterally.

Claim 15

A process for the preparation of compounds of the formula of claim 1, which comprises reacting a 4-aminophenyl 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-α(or β)-D-glucopyranosyl)-1-thio-α(or β)-D-glucopyranoside with phosgene in toluene and pyridine for 15-25 hours and purifying by chromatography, giving an N,N'-bis[4l-[[2,-3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-α(or β)-D-glucopyranosyl)-α(or β)-D-glucopyranosyl]thio]phenyl]urea; reacting with methanol saturated with ammonia at -5° to +5° C., giving an N,N'-bis[4-[[4-O-(α(or β)-D-glucopyranosyl)-α(or β)-D-glucopyranosyl]thio]phenyl]urea; reacting with triethylamine-sulfur trioxide in dry N,N-dimethylacetamide at 60°-70° C. for 40-60 hours giving the compounds of the above formula where M is NH + (C 2 H 5 ) 3 ; reacting with a cation-containing compound wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of piperidine, pyrazine, alkanolamine (C 2 -C.sub. 6) and cycloalkylamine (C 3 -C 6 ), and thereafter precipitating in ethanol, giving the desired products.